- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05351931
Role of Antisecretory Factor in Curative Radiochemotherapy for Anal Carcinoma (SALFLAC)
A Randomized Phase 2 Double-blind Placebo-controlled Trial Investigating the Effect of Salovum™ and SPC-flakes on Radiochemotherapy Induced Toxicity in Curative Treatment of Anal Carcinoma
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Curative RCT for AC is associated with considerable acute and long-term toxicity.
The acute toxicity derives from the combined effects of radiation and chemotherapy and is dominated by localized skin mucositis, diarrhoea and pain from radiation and nausea, fatigue, anemia/leukopenia, diarrhoea and general skin dryness from chemotherapy. These adverse effects are treated symptomatically with mostly modest effect and sometimes leads to the need for in-patient care and temporary stop of the RCT. Long-term toxicity is caused by radiation fibrosis and is dominated by impaired anal sphincter function leading to faeces incontinence, pelvic pain and reduced sexual function. Thus, new ways to efficiently counteract the RCT induced adverse effects are urgently needed.
Cholera induced diarrhoea, as well as other forms of diarrhoea-inducing agents, has been shown to elicit a stimulated, endogenous production of a protein, named "antisecretory factor" (ASF). This protein has been chemically characterized in detail. ASF acts by modulating secretion of water and ions but also counteracts inflammatory processes . ASF is also produced by hens fed on a diet of fermented grains or a specific diet of sugars and amino acids, leading to an accumulation of the ASF protein in the egg yolk. Spray dried yolk in the form of a powder is commercialized as Salovum registered by the EU authorities as "Food for specific medical purposes", i e is not adrug from a regulatory perspective.
Salovum rapidly increase the plasma (P-) ASF-concentration. Another way to increase ASF and, thus, to achieve benefit, is to induce its production/conversion by ingestion of oat flakes, specially processed (similar to malting) to contain the proper mix of sugars and amino acids. Such flakes are also commercially available (named SPC flakes) as "Food for specific medical purposes" and has been recommended or considered for a number of secretory pathological conditions, e g for treatment of Mb Meniére.
With this background the present study will investigate if induction of endogenous ASF by intake of SPC-flakes might be beneficial in AC patients to prevent RCT induced adverse events (AEs) and if administration of ASF from Salovum provides additional benefit (explorative).
Studietyp
Inskrivning (Förväntat)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Peter Nygren, MD
- Telefonnummer: +46704250719
- E-post: peter.nygren@igp.uu.se
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age ≥ 18 years.
- Histologically confirmed diagnosis of AC irrespective of tumour p16-status.
- Planned for curative RCT according to national care programme schedule B
- WHO performance status of 0 or 1.
- For patients planned for schedule C, they must be unsuitable for or not consenting to participation in the SWANCA trial.
- Able to understand study information and questionnaires and provide signed informed consent.
Exclusion Criteria:
- Patients with stoma.
- Contraindications to the investigational product, e g known or suspected hypersensitivity to the investigational products or expected inability to their use in accordance with the protocol.
- Contraindications to curative RCT in accordance with AC national care programme.
- Lack of suitability for participation in the study, e g expected difficulties to follow the protocol procedures, as judged by the investigator.
- Prior exposure to Salovum or SPC-flakes.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: SPC-flakes with or without Salovum
SPC-flakes flat dose of 75 g/d divided in 2 - 4 doses started 5 days prior to start of RCT and continued during the RCT.
Salovum egg powder 4 g/sachet.
Four sachets, ie 16 g q 8 h for 5 days prior to start of RCT.
The appropriate amount of Salovum is mixed with 100 - 200 ml of suitable liquid, eg fruit juice, and ingested orally.
|
Salovum and SPC-flakes are foods approved for specific medical purposes.
|
Placebo-jämförare: SPC-flakes placebo with or without Salovum placebo
SPC-placebo flat dose of 75 g/d divided in 2 - 4 doses started 5 days prior to start of RCT and continued during the RCT.
Salovum placebo egg powder 4 g/sachet.
Four sachets, ie 16 g q 8 h for 5 days prior to start of RCT.
The appropriate amount of Salovum placebo is mixed with 100 - 200 ml of suitable liquid, eg fruit juice, and ingested orally.
|
Salovum and SPC-flakes are foods approved for specific medical purposes.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Incidence of diarrhoea, fecal urgency, anal skin toxicity/mucositis and anal pain CTCAEv5.0 ≥ grade 2 during and up to 6 months after RCT. Anal skin toxicity/mucositis is to be verified by photos.
Tidsram: Through study completion, approximately 6 months
|
Treatment related toxicity
|
Through study completion, approximately 6 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Incidence and severity of other AEs according to CTCAEv5.0 during and up to 6 months after RCT.
Tidsram: Through study completion, approximately 6 months
|
Other treatment related toxicity
|
Through study completion, approximately 6 months
|
Change from baseline in patient reported hQoL and abdominal symptoms assessed by EORTC QLQ- 30 and the ANL27 subscale questionnaires as well as the Bristol Stool Form Scale.
Tidsram: Through study completion, approximately 6 months
|
PROMS
|
Through study completion, approximately 6 months
|
Increase in plasma (P)-ASF concentration from baseline to the day of start of RCT and to the end of treatment.
Tidsram: Days -1, 6 and 42
|
Pharmacodynamic outcome and compliance check
|
Days -1, 6 and 42
|
Relationships between P-ASF concentration, biomarkers reflecting inflammation and adverse events.
Tidsram: Through study completion, approximately 6 months
|
Biomarker assessments
|
Through study completion, approximately 6 months
|
Differences in primary and secondary endpoints between Salovum and placebo subgroups.
Tidsram: Through study completion, approximately 6 months
|
Assessment of added value of Salovum
|
Through study completion, approximately 6 months
|
Tumour response rate according to RECIST v1.1 and clinical examination at 2, 3 (radiology) and 6 months after stop of RCT.
Tidsram: Through study completion, approximately 6 months
|
Assessment of benefit, if any, from study products on clinical outcome
|
Through study completion, approximately 6 months
|
Disease free and overall survival at 3 and 6 months after stop of RCT.
Tidsram: At 3 and 6 months after stop of treatment
|
Assessment of benefit, if any, from study products on clinical outcome
|
At 3 and 6 months after stop of treatment
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Incidence of AEs CTCAEv5.0 grade ≥ 2 considered probably related to investigational products/placebo.
Tidsram: Through study completion, approximately 6 months
|
Adverse effects from study products
|
Through study completion, approximately 6 months
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Allmänna publikationer
- Ulgheri C, Paganini B, Rossi F. Antisecretory factor as a potential health-promoting molecule in man and animals. Nutr Res Rev. 2010 Dec;23(2):300-13. doi: 10.1017/S0954422410000193. Epub 2010 Aug 5.
- Laurenius A, Wangberg B, Lange S, Jennische E, Lundgren BK, Bosaeus I. Antisecretory factor counteracts secretory diarrhoea of endocrine origin. Clin Nutr. 2003 Dec;22(6):549-52. doi: 10.1016/s0261-5614(03)00057-8.
- Johansson E, Jennische E, Lange S, Lonnroth I. Antisecretory factor suppresses intestinal inflammation and hypersecretion. Gut. 1997 Nov;41(5):642-5. doi: 10.1136/gut.41.5.642.
- Cinausero M, Aprile G, Ermacora P, Basile D, Vitale MG, Fanotto V, Parisi G, Calvetti L, Sonis ST. New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury. Front Pharmacol. 2017 Jun 8;8:354. doi: 10.3389/fphar.2017.00354. eCollection 2017.
- Lonnroth I, Lange S. Purification and characterization of the antisecretory factor: a protein in the central nervous system and in the gut which inhibits intestinal hypersecretion induced by cholera toxin. Biochim Biophys Acta. 1986 Aug 6;883(1):138-44. doi: 10.1016/0304-4165(86)90144-3.
- Eriksson A, Shafazand M, Jennische E, Lange S. Effect of antisecretory factor in ulcerative colitis on histological and laborative outcome: a short period clinical trial. Scand J Gastroenterol. 2003 Oct;38(10):1045-9. doi: 10.1080/00365520310005064.
Studieavstämningsdatum
Studera stora datum
Studiestart (Förväntat)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- ASF 3
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Anal cancer
-
The Cleveland ClinicBard LtdAvslutad
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)AvslutadAnal skivepitelcancer | Steg III anal cancer AJCC v8 | Steg IIB anal cancer AJCC v8 | Steg IIIA anal cancer AJCC v8 | Steg IIIB anal cancer AJCC v8 | Steg IIIC anal cancer AJCC v8 | Steg I anal cancer AJCC v8 | Steg II anal cancer AJCC v8 | Steg IIA anal cancer AJCC v8 | Steg 0 Anal Cancer AJCC v8Förenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)AvslutadSteg III anal cancer AJCC v8 | Anal kanal skivepitelcancer | Steg IIB anal cancer AJCC v8 | Steg IIIA anal cancer AJCC v8 | Steg IIIB anal cancer AJCC v8 | Steg IIIC anal cancer AJCC v8 | Steg I anal cancer AJCC v8 | Steg II anal cancer AJCC v8 | Steg IIA anal cancer AJCC v8Förenta staterna
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RekryteringAnal basaloid karcinom | Anal Canal Cloacogenic Carcinom | Anal kanal skivepitelcancer | Anal marginal skivepitelcancer | Steg I anal cancer AJCC v8 | Steg IIA anal cancer AJCC v8Förenta staterna
-
Sun Yat-sen UniversityAnmälan via inbjudanAnal Canal Cancer | Anal skivepitelcancer | Anal cancer | Anal Cancer Steg I | Anal Cancer Steg II | Anal Cancer Steg IIIKina
-
National Cancer Institute (NCI)RekryteringAnal Canal Cloacogenic Carcinom | Metastaserande anal skivepitelcancer | Återkommande anal skivepitelcancer | Steg III anal cancer AJCC v8 | Steg IV anal cancer AJCC v8 | Ooperabelt analt skivepitelcancer | Anal basaloid skivepitelcancerFörenta staterna
-
Tel-Aviv Sourasky Medical CenterRekryteringIleal påse Anal anastomosIsrael
-
National Cancer Institute (NCI)RekryteringHIV-infektion | Anal skivepitelcancer | Anal Canal Cloacogenic Carcinom | Steg III anal cancer AJCC v8 | Steg III rektalcancer AJCC v8 | Steg II rektalcancer AJCC v8 | Anal marginal skivepitelcancer | AIDS-relaterat analt karcinom | Rektal skivepitelcancer | Steg I anal cancer AJCC v8 | Steg II anal cancer AJCC... och andra villkorFörenta staterna
-
National Cancer Institute (NCI)Canadian Cancer Trials GroupAktiv, inte rekryterandeAnal Canal Cloacogenic Carcinom | Steg III anal cancer AJCC v8 | Anal marginal skivepitelcancer | Steg IIB anal cancer AJCC v8 | Anal basaloid skivepitelcancerFörenta staterna, Kanada
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRekryteringAnal Canal Cancer | Anal skivepitelcancer | Anal cancer | Anal Cancer Steg IIIKina
Kliniska prövningar på Salovum and SPC-flakes or corresponding placebo
-
Henrik LindmanRekryteringDiarre | Negativ droghändelse | Bröstcancer i ett tidigt stadiumSverige
-
Uppsala University HospitalSwedish Cancer Society; Lantmännen AB; Sjöbergstiftelsen; Onkologiska klinikens...RekryteringDihydropyrimidin-inducerad gastrointestinal toxicitet vid kolorektal cancerSverige